Patents Assigned to Zhejiang DTRM Biopharma Co. Ltd.
-
Patent number: 11622965Abstract: The present disclosure provides methods of treating lymphoid malignancies such as B cell malignancies using a BTK inhibitor in the described therapeutic regimens.Type: GrantFiled: October 26, 2018Date of Patent: April 11, 2023Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Patent number: 11369620Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: GrantFiled: February 13, 2020Date of Patent: June 28, 2022Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Publication number: 20200323885Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: ApplicationFiled: February 13, 2020Publication date: October 15, 2020Applicant: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Publication number: 20200289517Abstract: The present disclosure provides methods of treating lymphoid malignancies such as B cell malignancies using a BTK inhibitor in the described therapeutic regimens.Type: ApplicationFiled: October 26, 2018Publication date: September 17, 2020Applicant: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Patent number: 10596183Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: GrantFiled: September 6, 2018Date of Patent: March 24, 2020Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Patent number: 10537587Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: GrantFiled: September 6, 2018Date of Patent: January 21, 2020Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Patent number: 10300066Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.Type: GrantFiled: November 22, 2017Date of Patent: May 28, 2019Assignee: Zhejiang DTRM Biopharma Co. Ltd.Inventor: Wei He
-
Publication number: 20180360853Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: ApplicationFiled: September 6, 2018Publication date: December 20, 2018Applicant: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Patent number: 10098900Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: GrantFiled: June 20, 2017Date of Patent: October 16, 2018Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Publication number: 20180207161Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.Type: ApplicationFiled: November 22, 2017Publication date: July 26, 2018Applicant: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Patent number: 9861636Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.Type: GrantFiled: November 18, 2016Date of Patent: January 9, 2018Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Patent number: 9717745Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: GrantFiled: June 15, 2016Date of Patent: August 1, 2017Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Publication number: 20170065594Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.Type: ApplicationFiled: November 18, 2016Publication date: March 9, 2017Applicant: Zhejiang DTRM Biopharma Co. Ltd.Inventor: Wei He
-
Patent number: 9532990Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.Type: GrantFiled: March 18, 2016Date of Patent: January 3, 2017Assignee: Zhejiang DTRM Biopharma Co. Ltd.Inventor: Wei He
-
Publication number: 20160324878Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: ApplicationFiled: June 15, 2016Publication date: November 10, 2016Applicant: Zhejiang DTRM Biopharma Co. Ltd.Inventor: Wei He
-
Publication number: 20160200730Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.Type: ApplicationFiled: March 18, 2016Publication date: July 14, 2016Applicant: Zhejiang DTRM Biopharma Co. Ltd.Inventor: Wei He